Your browser is out of date
With an updated browser, you will have a better Medtronic web site experience. Update my browser now.
,
4% - 22% هي نسبة فقدان الوزن التي تحققها أدوية السمنة
*34,35
12. Pilitsi E, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metab Clin Exp 2019; 92: 170–92.
31. Lee PC, Dixon J. Pharmacotherapy for obesity. Aust Fam Phys. 2017; 46(7): 472–7
32. Saxenda Product Information. Available at https://www.tga.gov.au/sites/default/files/auspar-liraglutide-190429-pi.pdf Accessed December 2019.
33. Contrave Product Information. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2019-PI-01018-1&d=201912201016933 Accessed December 2019.
34 Pilitsi E, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metab Clin Exp 2019; 92: 170-92.
35 Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038